Screening through charts of positions, there are a few names now back over their 20, 50, and 200 day moving averages -
NuVasive (NUVA) is one. I don't see any news in particular but a
nice article in Investors Business Daily from late October I thought I'd bring here; I always like their stories because they usually can explain some more complicated fundamental stories in "layman's terms".
The stock market action (aside from yesterday) continues to be "student body left" or "student body right" - everything is good or everything is bad trading. While it feels better to the upside then downside, it is not really an investing atmosphere when individual stocks continue to not differentiate and everything has to be either bought or sold en masse. I will be interested to see the markets reaction later this week to retail numbers and the jobs report...
Still trying to find a leadership group if there is any sustained move up - right now the most oversold stocks are simply reverting to a mean but nothing has been consistent - I still have hopes that healthcare should be one group that works over a longer period since it should be relatively immune to a recession.
NuVasive has my favorite business model -
razor and blade - sell the razor once, sell the blades forever. Unfortunately there are a lot of legal expenses hitting due to a patent suit, but that's not an operational issue - just a cost that is a pain to maintain.
- In a stalled economy, investors might be rightfully concerned about weak spending for high-ticket capital gear. That's certainly been a concern for followers of medical-equipment stocks. Some might lump medical-device maker NuVasive in that boat. That would be unfair.
- Most of NuVasive's (NasdaqGS:NUVA - News) sales are from dozens of small disposal tools and grafts used to perform a minimally invasive lateral back-fusion surgery it developed with specialists. Analysts say the economy doesn't much matter when it comes to back surgeries.